Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Nov 27, 2024 8:14am
118 Views
Post# 36333057

RE:RE:Spectral on Linkedin Today

RE:RE:Spectral on Linkedin Today

A few more comments. 

suggests average death rate worldwide ( per annum) from ESS at about 3 million. (30 million will gets form of SS, 5-7 million of those might get ESS , while half of those will die) 

The holocaust claimed 6 million lives over 5-6 years. ( while today ESS will claim 15 million or more over an equivalent period of time) 

I wonder if CG sees an appropriately large enough worldwide target market at  $15,000 per patient ( doing the math that = $45 Billion USD)?  - and that's if you only count the half that will die as a possible treatment group!

more fun with math using their numbers. 

6 million diagnostic tests ( EAAs) at $200 USD = $1.2 Billion. 

As a triage test for 30 million SS cases, the number is 5 times larger than that ... per annum !  ... for just the diagnostic !?

MM 

<< Previous
Bullboard Posts
Next >>